Fig. 3From: The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysisForest plot of the overall effect between nivolumab-ipilimumab combined therapy and nivolumab monotherapy. a Complete response (CR). b Partial response (PR). c Objective response rate (ORR)Back to article page